Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.36 |
| ▸ | CD69 | Q07108 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26115607 | 1.00 | BTK (0.36) | BTKCD69CYP3A4CYP2C9ABL1 | |
| SCHEMBL26117214 | 0.88 | BTK (0.34) | BTKCD69CYP3A4CYP2C9 | |
| SCHEMBL30064460 | 0.88 | BTK (0.34) | BTKCD69CYP3A4CYP2C9 | |
| SCHEMBL26117219 | 0.88 | BTK (0.34) | BTKCD69CYP3A4CYP2C9 | |
| SCHEMBL23816264 | 0.86 | BTK (0.46) | BTK | |
| SCHEMBL26114422 | 0.84 | HDAC4 (0.35) | BTKKRAS | |
| SCHEMBL26114427 | 0.84 | HDAC4 (0.35) | BTKKRAS | |
| SCHEMBL23816033 | 0.82 | CCND3 (0.35) | BTKKRAS | |
| SCHEMBL26114028 | 0.82 | CCND3 (0.35) | BTKKRAS | |
| SCHEMBL30063454 | 0.77 | BTK (0.35) | BTKCD69CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BTK 1/4885CD69 3458/4885CYP3A4 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.